About Shionogi
About Shionogi
About
About
Company Profile
BRAND STATEMENT
Our Company
Compliance
Corporate Governance
SHIONOGI Infectious Disease Weeks
Message from Top Management
Philosophy
Business Strategy
Business Activities
Shionogi's Strength
Group Companies
History
Policies
Compliance
Compliance Promotion Structure and Initiatives
Commitment to Tax Compliance
Ensuring High Ethical Standards and Transparency in Business Activities
Corporate Governance
Basic Views and Guidelines on Corporate Governance
Corporate Governance System
Board
Shareholdings
Sustainability
Sustainability
Sustainability
Sustainability
Material Issues
Environment
Society
Governance
Address the problem of antimicrobial resistance (AMR)
Access to healthcare
Stakeholder Engagement
Sustainability disclosure and evaluation
Sustainability-related information
Environment
Policy / Approach
Environmental Topics
Initiatives for Each Theme
Information Disclosure / Data
Society
Ensuring quality and safety in products and services
Attractive workplace
Respect Human Rights
Supply Chain Management
Social contribution activities
Governance
Corporate Governance
Risk Management
Compliance
Address the problem of antimicrobial resistance (AMR)
Our promise
Background of addressing the problem of antimicrobial resistance (AMR)
Long-term commitment to improving R&D to provide novel treatments for infectious diseases
Combating challenge of AMR
AMR
Shionogi AMR Position Paper
Access to healthcare
Developing innovative therapies to address unmet needs
Promote proper use of medicines
Improving affordability for patients in need
Improving access to healthcare services in developing countries
Stakeholder Engagement
Engagement with shareholders and investors
Engagement with customers
Engagement with employees
Engagement with society
Annual Report / Integrated Report / Environment Report
Data
External evaluation
About United Nations Global Compact
Innovation
Innovation
Innovation
Innovation
R&D
Corporate Venture Capital
Pipeline
IP Strategy
Wastewater-based Epidemiology Surveillance Service
R&D
Overview of R&D
Drug discovery
Clinical Development
Digital therapy
Investigator-Initiated Research
Open Innovation
SHIONOGI Journal
News
SPmenu
SPmenu
About
Back
About
Company Profile
SHIONOGI Journal
BRAND STATEMENT
Our Company
Compliance
Corporate Governance
SHIONOGI Infectious Disease Weeks
Back
Message from Top Management
Philosophy
Business Strategy
Business Activities
Shionogi's Strength
Group Companies
History
Policies
Back
Compliance
SHIONOGI Group Compliance Policy
Compliance Promotion Structure and Initiatives
Commitment to Tax Compliance
Ensuring High Ethical Standards and Transparency in Business Activities
Back
Corporate Governance
Basic Views and Guidelines on Corporate Governance
Corporate Governance System
Board
Shareholdings
Sustainability
Back
Sustainability
Material Issues
Environment
Society
Governance
Address the problem of antimicrobial resistance (AMR)
Access to healthcare
Stakeholder Engagement
Sustainability disclosure and evaluation
Sustainability-related information
Back
Environment
Policy / Approach
Environmental Topics
Initiatives for Each Theme
Information Disclosure / Data
Back
Society
Ensuring quality and safety in products and services
Attractive workplace
Respect Human Rights
Supply Chain Management
Social contribution activities
Back
Governance
Corporate Governance
Risk Management
Compliance
Back
Address the problem of antimicrobial resistance (AMR)
Our promise
Background of addressing the problem of antimicrobial resistance (AMR)
Long-term commitment to improving R&D to provide novel treatments for infectious diseases
Combating challenge of AMR
AMR
Shionogi AMR Position Paper
Back
Access to healthcare
Developing innovative therapies to address unmet needs
Promote proper use of medicines
Improving affordability for patients in need
Improving access to healthcare services in developing countries
Back
Stakeholder Engagement
Engagement with shareholders and investors
Engagement with customers
Engagement with employees
Engagement with society
Back
Annual Report / Integrated Report / Environment Report
Data
External evaluation
Back
About United Nations Global Compact
Innovation
Back
Innovation
R&D
Corporate Venture Capital
Pipeline
IP Strategy
Wastewater-based Epidemiology Surveillance Service
Back
R&D
Overview of R&D
Drug discovery
Clinical Development
Digital therapy
Investigator-Initiated Research
Open Innovation
SHIONOGI Journal
News
Investors
Contact Us
Careers
Search
English
Worldwide
HOME
News
Presentation Materials for FY2025 3Q financial results
Notice
2026/01/30
Presentation Materials for FY2025 3Q financial results
